FDA To Address PDE-5 Inhibitors And HIV Risk At Consensus Conference
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency plans to review data related to the use of erectile dysfunction therapies and their relationship to HIV transmission.
You may also be interested in...
Erectile Dysfunction Class Labeling Does Not Assert Causal Link To Vision Loss
Labeling revisions for Viagra, Levitra and Cialis will add information about NAION adverse events, but states that “it is not possible to determine whether these events are related directly to the use of PDE5 inhibitors or to other factors.”
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.